Removing Pediatric OTC Cold Drugs Would Create New Problems – CHPA
This article was originally published in The Tan Sheet
Executive Summary
Pulling pediatric cough/cold products off the shelf in an effort to curb adverse events could lead to "unintended" consequences, such as parents inappropriately giving children adult medication, according to results of a Consumer Healthcare Products Association study
You may also be interested in...
Calls For Cough/Cold Collaboration As FDA Inches Toward Rulemaking
As FDA embarks on a lengthy rulemaking process to address pediatric OTC cough/cold products, the agency has strategies outside the regulatory framework available to effect any more immediate changes it deems necessary
Novartis Pediatric Triaminic Target Of Proposed Class Action
Novartis' Triaminic Daytime Cold & Cough, one of the OTC children's cold product lines voluntarily withdrawn from the market in 2007 due to concerns about misuse, is the subject of proposed class action
FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6
An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds